SLNO soleno.life Earnings growth forecast for next year

Corporate emblem and logo of Soleno Therapeutics, Inc. (SLNO)

Soleno Therapeutics (SLNO) aims for leadership in the Prader-Willi syndrome therapy niche, supported by strong research positions. However, long-term success depends on FDA approval and the commercialization of the DCCR drug. A potential exit from the development stage is only possible through acquisition by a tech giant. The consensus estimate for net profit growth rates reflects a search for market equilibrium, with the value holding at 73.20.

Soleno (SLNO): Expected net earnings per share growth next year from 07/04/2022 to 05/30/2026

SLNO (Soleno Therapeutics Inc): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Initial company analysis:SLNO, soleno.life
Finished products of Soleno Therapeutics, Inc.

This indicator reflects the consensus forecast for profit growth rates in the coming period by measuring the difference between current and expected EPS. By analyzing the forward net income trend with a value of 73.20, an investor assesses market expectations for the monetization of DCCR by Soleno Therapeutics (SLNO), where monopoly pricing power amid inelastic demand for the Prader-Willi syndrome treatment will serve as the primary growth driver.

Analysis of competing companies

ASND (Ascendis) - Earnings growth forecast for next year|Earnings growth forecast for next year Madrigal Pharmaceuticals|Earnings growth forecast for next year CORT|Net earnings per share growth forecast for next year RYTM (Rhythm Pharma)|Net earnings per share growth forecast for next year akerotx.com AKRO|Metsera Therapeutics (MTSR) - Expected net earnings per share growth next year|MLTX - Net earnings per share growth forecast for next year|CRNX: Net earnings per share growth forecast for next year|NAMS: Earnings growth forecast for next year|FOLD - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year 89bio Pharma|Agios Corp (AGIO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year structuretx.com (GPCR)|Expected earnings per share growth for next year mimedx.com MDXG|Net earnings per share growth forecast for next year Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Net earnings per share growth forecast for next year|MBX: Expected earnings per share growth for next year|Altimmune Corp - Projected earnings per share increase next year|Aardvark Therapeutics Inc (AARD) - Net earnings per share growth forecast for next year|Net earnings per one share growth forecast for next year Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Earnings growth forecast for next year|Expected earnings per share growth for next year Biomea Fusion (BMEA)|Earnings growth forecast for next year QNCX|Projected earnings per share increase next year GUTS|Earnings growth forecast for next year VTVT (vTv Therapeutics Inc.)|Expected earnings per share trend next year ATPC|Pluristem Therapeutics - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year synlogictx.com SYBX|LPCN: Earnings growth forecast for next year|Matinas BioPharma Holdings, Inc. - Expected earnings per share trend next year|SPRB (Spruce Biosciences Inc.) - Earnings growth forecast for next year|galecto.com (GLTO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year organovo.com ONVO|Radius Health (RDUS) - Expected net earnings per share growth next year